Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells

Cancer Immunology, Immunotherapy : CII
Jon A Kyte, Gustav Gaudernack

Abstract

We have developed immuno-gene therapy for malignant melanoma and prostate cancer. The therapy is based on monocyte-derived dendritic cells (DCs) that are transfected with autologous melanoma-mRNA or mRNA from three prostate cancer cell lines (DU-145, LN-CaP and PC-3). A broad spectrum of tumour-associated antigens will be included in both DC-vaccines. The use of autologous melanoma-mRNA moreover allows targeting of individual tumour antigens that are specific to each patient. Effective protocols have been established for mRNA-transfection by square wave electroporation and for the generation of clinical grade DCs. A full scale preclinical evaluation demonstrated in vitro T cell responses in 6/6 advanced melanoma patients. The responses were specific to antigens encoded by the transfected tumour-mRNA. Recently, we have conducted two phase I/II trials, in advanced malignant melanoma and androgen-resistant prostate cancer. Successful vaccine preparations were obtained for all 41 patients elected. No serious adverse effects were observed. Specific T cell responses (T cell proliferation and/or IFNgamma ELISPOT) were demonstrated in 9/19 evaluable melanoma patients and in 12/19 prostate cancer patients. The response rates were higher...Continue Reading

References

Jan 1, 1970·Progress in Experimental Tumor Research·F M Burnet
Dec 11, 1995·International Journal of Cancer. Journal International Du Cancer·M MarchandY Humblet
Apr 1, 1998·Nature·J Banchereau, R M Steinman
Dec 23, 1999·Clinical Immunology : the Official Journal of the Clinical Immunology Society·R P BurnsA A Gaspari
Feb 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·J GongD Kufe
Jul 21, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·J GongD Kufe
Oct 31, 2002·Nature Immunology·Gavin P DunnRobert D Schreiber
Apr 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·F Stephen HodiGlenn Dranoff
Apr 25, 2003·Cancer·Stephen C Rubin
May 4, 2004·Nature Medicine·Carl G FigdorCornelis J M Melief
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard L KaufmanLouis M Weiner
Jul 6, 2004·Immunological Reviews·Eli Gilboa, Johannes Vieweg
Jul 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edward A HirschowitzJohn Yannelli
Feb 8, 2005·The Journal of Clinical Investigation·Daniel E SpeiserPedro Romero
Mar 8, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Zhen SuJohannes Vieweg
Apr 2, 2005·Nature Reviews. Immunology·Jacques Banchereau, A Karolina Palucka
May 3, 2005·Cancer Immunology, Immunotherapy : CII·J WiereckyP Brossart
Sep 28, 2005·Cancer Immunology, Immunotherapy : CII·Margarita SalcedoThierry Velu
Oct 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antoni RibasJesus Gomez-Navarro
Nov 26, 2005·The Journal of Clinical Investigation·Jens DannullJohannes Vieweg
Feb 24, 2006·Cancer Immunology, Immunotherapy : CII·Paal F BrunsvigGustav Gaudernack

❮ Previous
Next ❯

Citations

Sep 2, 2006·Cancer Immunology, Immunotherapy : CII·Jon Amund KyteGustav Gaudernack
Mar 22, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Barbara-ann GuinnAlbert B Deisseroth
Aug 7, 2009·Human Gene Therapy·Evelien L J M SmitsViggo F I Van Tendeloo
Dec 30, 2009·Oligonucleotides·Sigurd BøeEivind Hovig
Mar 5, 2008·Journal of Immunotherapy·Lisa H ButterfieldAntoni Ribas
Sep 29, 2011·The Cancer Journal·Charles G Drake
Aug 14, 2010·Journal of Biomedicine & Biotechnology·Matteo VergatiKwong Y Tsang
Apr 9, 2008·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Mikako HiuraYuji Hinoda
Aug 7, 2008·Experimental Oncology·V F Chekhun
Mar 1, 2009·Immunotherapy·Thomas SimonMarc Grégoire
Jul 20, 2010·Immunotherapy·Elzbieta Pajtasz-Piasecka, Marie Indrová
Mar 1, 2011·Chinese Journal of Cancer·Chao ZhangWen-Lin Huang
Nov 5, 2008·Expert Review of Vaccines·John A Mikszta, Philippe E Laurent
Apr 25, 2009·Expert Opinion on Investigational Drugs·Jon Amund Kyte
Apr 28, 2009·Expert Opinion on Biological Therapy·Wellington PhamJohn C Gore
Oct 20, 2010·Expert Opinion on Biological Therapy·Michael R ShurinAnatoli M Malyguine
Oct 26, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Geertrui TavernierJoanna Rejman
Aug 22, 2008·Seminars in Immunology·Matthew R Buckwalter, Pramod K Srivastava
Feb 15, 2013·Nucleic Acid Therapeutics·Jens Andreas Lindin JørgensenSigurd Leinæs Bøe
Dec 20, 2008·Journal of Internal Medicine·C R Rinaldo
Apr 22, 2008·Biochemical and Biophysical Research Communications·Akihiro HosoiKazuhiro Kakimi
Jan 19, 2008·Cytotherapy·H EichlerUNKNOWN Biomedical Excellence for Safer Transfusion Collaborative
Nov 22, 2012·Oncoimmunology·Lorenzo GalluzziGuido Kroemer
May 17, 2014·Frontiers in Immunology·Harm WestdorpI Jolanda M de Vries
Oct 18, 2016·Cytotherapy·Rebecca S Abraham, Duane A Mitchell
Feb 10, 2018·Immunotherapy·Md Kamal HossainVasso Apostolopoulos
Jun 16, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nicolás HerbertMargot Zöller

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.